Giovanni B Frisoni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/993382/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
2	Alzheimer's disease. Lancet, The, 2016, 388, 505-517.	13.7	2,430
3	Distinct patterns of brain activity in young carriers of the <i>APOE</i> -ε4 allele. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7209-7214.	7.1	1,524
4	The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 67-77.	10.1	1,505
5	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.8	1,318
6	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	10.2	1,242
7	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology, 2016, 87, 539-547.	1.1	1,216
8	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
9	Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiology of Aging, 2017, 49, 60-68.	3.1	870
10	Brain atrophy in Alzheimer's Disease and aging. Ageing Research Reviews, 2016, 30, 25-48.	10.9	507
11	Resting state fMRI in Alzheimer's disease: beyond the default mode network. Neurobiology of Aging, 2012, 33, 1564-1578.	3.1	497
12	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	10.2	464
13	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	10.2	432
14	Functional network disruption in the degenerative dementias. Lancet Neurology, The, 2011, 10, 829-843.	10.2	422
15	The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain, 2007, 130, 720-730.	7.6	408
16	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496.	10.2	396
17	Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurology, The, 2003, 2, 79-88.	10.2	354
18	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.8	354

#	Article	IF	CITATIONS
19	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
20	Neuropsychiatric Syndromes in Dementia. Dementia and Geriatric Cognitive Disorders, 2007, 24, 457-463.	1.5	305
21	Consensus paper: Combining transcranial stimulation with neuroimaging. Brain Stimulation, 2009, 2, 58-80.	1.6	299
22	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
23	White Matter Damage in Alzheimer Disease and Its Relationship to Gray Matter Atrophy. Radiology, 2011, 258, 853-863.	7.3	263
24	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	12.8	263
25	Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study. Clinical Neurophysiology, 2006, 117, 252-268.	1.5	260
26	Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy. Nature Reviews Neurology, 2014, 10, 620-633.	10.1	258
27	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
28	Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study. Human Brain Mapping, 2006, 27, 162-172.	3.6	253
29	A Panâ€ <scp>E</scp> uropean Study of the <i>C9orf72</i> Repeat Associated with <scp>FTLD</scp> : Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	2.5	247
30	A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia. Neuroinformatics, 2014, 12, 575-593.	2.8	240
31	Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection. Lancet Neurology, The, 2015, 14, 1037-1053.	10.2	233
32	Suspected non-Alzheimer disease pathophysiology — concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	10.1	230
33	Hippocampus and entorhinal cortex in frontotemporal dementia and Alzheimer's disease: a morphometric MRI study. Biological Psychiatry, 2000, 47, 1056-1063.	1.3	210
34	Mapping local hippocampal changes in Alzheimer's disease and normal ageing with MRI at 3 Tesla. Brain, 2008, 131, 3266-3276.	7.6	206
35	Imaging markers for Alzheimer disease. Neurology, 2013, 81, 487-500.	1.1	204
36	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	10.2	203

#	Article	IF	CITATIONS
37	Contrasting Results Between Caregiver's Report and Direct Assessment of Activities of Daily Living in Patients Affected by Mild and Very Mild Dementia: The Contribution of the Caregiver's Personal Characteristics. Journal of the American Geriatrics Society, 1999, 47, 196-202.	2.6	181
38	Qualitative Estimates of Medial Temporal Atrophy as a Predictor of Progression From Mild Cognitive Impairment to Dementia. Archives of Neurology, 2007, 64, 108.	4.5	178
39	Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. European Psychiatry, 2005, 20, 490-496.	0.2	177
40	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474.	0.8	176
41	Geriatric Index of Comorbidity: validation and comparison with other measures of comorbidity. Age and Ageing, 2002, 31, 277-285.	1.6	173
42	Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study. Journal of Alzheimer's Disease, 2014, 40, 687-700.	2.6	173
43	Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium. Dementia and Geriatric Cognitive Disorders, 2008, 25, 1-8.	1.5	167
44	A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer's disease. Journal of Magnetic Resonance Imaging, 2004, 19, 274-282.	3.4	163
45	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.8	162
46	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.1	161
47	Fronto-parietal coupling of brain rhythms in mild cognitive impairment: A multicentric EEG study. Brain Research Bulletin, 2006, 69, 63-73.	3.0	159
48	Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations. NeuroImage, 2013, 83, 472-484.	4.2	157
49	Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic lateâ€onset alzheimer's disease. Annals of Neurology, 1995, 37, 596-604.	5.3	153
50	Frontal white matter volume and delta EEG sources negatively correlate in awake subjects with mild cognitive impairment and Alzheimer's disease. Clinical Neurophysiology, 2006, 117, 1113-1129.	1.5	150
51	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73.	3.1	150
52	Mild cognitive impairment with subcortical vascular features. Journal of Neurology, 2002, 249, 1423-1432.	3.6	149
53	Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease. NeuroImage, 2009, 44, 123-135.	4.2	145
54	MRI of hippocampus and entorhinal cortex in mild cognitive impairment: A follow-up study. Neurobiology of Aging, 2008, 29, 31-38.	3.1	143

#	Article	IF	CITATIONS
55	Brain anatomy of persistent violent offenders: More rather than less. Psychiatry Research - Neuroimaging, 2008, 163, 201-212.	1.8	142
56	Resting state cortical electroencephalographic rhythms are related to gray matter volume in subjects with mild cognitive impairment and Alzheimer's disease. Human Brain Mapping, 2013, 34, 1427-1446.	3.6	142
57	Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial. British Journal of Psychiatry, 2005, 187, 450-455.	2.8	135
58	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
59	MRI-Based Automated Computer Classification of Probable AD Versus Normal Controls. IEEE Transactions on Medical Imaging, 2008, 27, 509-520.	8.9	133
60	Directionality of EEG synchronization in Alzheimer's disease subjects. Neurobiology of Aging, 2009, 30, 93-102.	3.1	132
61	Shunt-Associated Migraine Responds Favorably to Atrial Septal Repair. Stroke, 2006, 37, 430-434.	2.0	127
62	Frontotemporal dementia as a neural system disease. Neurobiology of Aging, 2005, 26, 37-44.	3.1	126
63	Survey of Protocols for the Manual Segmentation of the Hippocampus: Preparatory Steps Towards a Joint EADC-ADNI Harmonized Protocol. Journal of Alzheimer's Disease, 2011, 26, 61-75.	2.6	125
64	Resting state cortical EEG rhythms in Alzheimer's disease. Supplements To Clinical Neurophysiology, 2013, 62, 223-236.	2.1	123
65	Delphi definition of the EADCâ€ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimer's and Dementia, 2015, 11, 126-138.	0.8	123
66	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). Neurology, 2015, 84, 508-515.	1.1	122
67	Disease Tracking Markers for Alzheimer's Disease at the Prodromal (MCI) Stage. Journal of Alzheimer's Disease, 2011, 26, 159-199.	2.6	120
68	Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease. Human Brain Mapping, 2010, 31, 1862-1875.	3.6	119
69	Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 2011, 95, 579-593.	5.7	119
70	Cortex and amygdala morphology in psychopathy. Psychiatry Research - Neuroimaging, 2011, 193, 85-92.	1.8	118
71	In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease. Journal of Neurology, 2009, 256, 916-924.	3.6	116
72	APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. NeuroImage, 2011, 55, 909-919.	4.2	116

#	Article	IF	CITATIONS
73	Physical Performance Test and Activities of Daily Living Scales in the Assessment of Health Status in Elderly People. Journal of the American Geriatrics Society, 1993, 41, 1109-1113.	2.6	113
74	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.8	113
75	Relationship Between Functional Loss Before Hospital Admission and Mortality in Elderly Persons With Medical Illness. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1180-1183.	3.6	111
76	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology, 2013, 80, 1124-1132.	1.1	110
77	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	7.6	109
78	Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project. Neurobiology of Aging, 2012, 33, 2533-2550.	3.1	108
79	Metabolic Networks Underlying Cognitive Reserve in Prodromal Alzheimer Disease: A European Alzheimer Disease Consortium Project. Journal of Nuclear Medicine, 2013, 54, 894-902.	5.0	108
80	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.8	108
81	The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiology of Aging, 2003, 24, 95-103.	3.1	107
82	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
83	Training labels for hippocampal segmentation based on the EADCâ€ADNI harmonized hippocampal protocol. Alzheimer's and Dementia, 2015, 11, 175-183.	0.8	105
84	The effect of white matter lesions on cognition in the elderly—small but detectable. Nature Clinical Practice Neurology, 2007, 3, 620-627.	2.5	104
85	Resting EEG sources correlate with attentional span in mild cognitive impairment and Alzheimer's disease. European Journal of Neuroscience, 2007, 25, 3742-3757.	2.6	101
86	Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects. NeuroImage, 2014, 101, 390-403.	4.2	99
87	Multicenter stability of diffusion tensor imaging measures: A European clinical and physical phantom study. Psychiatry Research - Neuroimaging, 2011, 194, 363-371.	1.8	98
88	Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiology of Aging, 2010, 31, 1787-1798.	3.1	97
89	Distinctive Clinical Features of Mild Cognitive Impairment with Subcortical Cerebrovascular Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 196-203.	1.5	96
90	Delirium Superimposed on Dementia Predicts 12-Month Survival in Elderly Patients Discharged From a Postacute Rehabilitation Facility. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2007, 62, 1306-1309.	3.6	96

#	Article	IF	CITATIONS
91	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. Journal of Hepatology, 2011, 55, 564-573.	3.7	96
92	Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 36-45.	6.4	95
93	Insulin Resistance in Cognitive Impairment. Archives of Neurology, 2005, 62, 1067.	4.5	94
94	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	7.7	93
95	Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2015, 36, 556-570.	3.1	93
96	Italian community norms for the Brief Symptom Inventory in the elderly. British Journal of Clinical Psychology, 1993, 32, 209-213.	3.5	92
97	Apolipoprotein E and alpha brain rhythms in mild cognitive impairment: A multicentric Electroencephalogram study. Annals of Neurology, 2006, 59, 323-334.	5.3	92
98	Cortical sources of resting state electroencephalographic rhythms in Parkinson's disease related dementia and Alzheimer's disease. Clinical Neurophysiology, 2011, 122, 2355-2364.	1.5	91
99	Relating one-year cognitive change in mild cognitive impairment to baseline MRI features. NeuroImage, 2009, 47, 1363-1370.	4.2	90
100	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.8	90
101	Harmonization of magnetic resonanceâ€based manual hippocampal segmentation: A mandatory step for wide clinical use. Alzheimer's and Dementia, 2011, 7, 171-174.	0.8	88
102	Anatomical MRI and DTI in the Diagnosis of Alzheimer's Disease: A European Multicenter Study. Journal of Alzheimer's Disease, 2012, 31, S33-S47.	2.6	86
103	Alexithymia in healthy women: A brain morphology study. Journal of Affective Disorders, 2009, 114, 208-215.	4.1	85
104	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. NeuroImage, 2016, 124, 442-454.	4.2	85
105	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
106	Worldwide Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 337-342.	0.8	84
107	Reduced cerebrovascular reactivity in young adults carrying the <i>APOE</i> ε4 allele. Alzheimer's and Dementia, 2015, 11, 648.	0.8	84
108	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. JAMA Neurology, 2016, 73, 1417.	9.0	84

#	Article	IF	CITATIONS
109	Effects of hormone therapy on brain morphology of healthy postmenopausal women. Menopause, 2006, 13, 584-591.	2.0	81
110	The effect of chronic diseases on physical function. Comparison between activities of daily living scales and the Physical Performance Test. Age and Ageing, 1997, 26, 281-287.	1.6	80
111	Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer's and Dementia, 2009, 5, 307-317.	0.8	80
112	Microstructural Diffusion Changes are Independent of Macrostructural Volume Loss in Moderate to Severe Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 963-976.	2.6	80
113	Probabilistic disease progression modeling to characterize diagnostic uncertainty: Application to staging and prediction in Alzheimer's disease. NeuroImage, 2019, 190, 56-68.	4.2	80
114	Summary Metrics to Assess Alzheimer Disease–Related Hypometabolic Pattern with ¹⁸ F-FDG PET: Head-to-Head Comparison. Journal of Nuclear Medicine, 2012, 53, 592-600.	5.0	79
115	Atrial Fibrillation and Cognitive Disorders in Older People. Journal of the American Geriatrics Society, 2000, 48, 387-390.	2.6	78
116	Electroencephalographic Rhythms in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-11.	2.0	77
117	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 421.	0.8	77
118	Genotype (cystatin C) and EEG phenotype in Alzheimer disease and mild cognitive impairment: A multicentric study. NeuroImage, 2006, 29, 948-964.	4.2	76
119	Integrating longitudinal information in hippocampal volume measurements for the early detection of Alzheimer's disease. Neurolmage, 2016, 125, 834-847.	4.2	76
120	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiology of Aging, 2017, 55, 143-158.	3.1	76
121	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2019, 82, 102-109.	3.1	76
122	Classification of Single Normal and Alzheimer's Disease Individuals from Cortical Sources of Resting State EEG Rhythms. Frontiers in Neuroscience, 2016, 10, 47.	2.8	73
123	Predictors of Mortality and Institutionalization in Alzheimer Disease Patients 1 Year after Discharge from an Alzheimer Dementia Unit. Dementia and Geriatric Cognitive Disorders, 1995, 6, 108-112.	1.5	72
124	Cortical Sources of Resting State EEG Rhythms are Sensitive to the Progression of Early Stage Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 1015-1035.	2.6	72
125	Fractional Anisotropy Changes in Alzheimer's Disease Depend on the Underlying Fiber Tract Architecture: A Multiparametric DTI Study using Joint Independent Component Analysis. Journal of Alzheimer's Disease, 2014, 41, 69-83.	2.6	71
126	Prediction of AD dementia by biomarkers following the NIAâ€AA andÂIWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71

#	Article	IF	CITATIONS
127	Determinants of Health and Disability in Ageing Population: The COURAGE in Europe Project (Collaborative Research on Ageing in Europe). Clinical Psychology and Psychotherapy, 2014, 21, 193-198.	2.7	70
128	Visual assessment of medial temporal atrophy on MR films in Alzheimer's disease: comparison with volumetry. Aging Clinical and Experimental Research, 2005, 17, 8-13.	2.9	68
129	Resting State Cortical Rhythms in Mild Cognitive Impairment and Alzheimer's Disease: Electroencephalographic Evidence. Journal of Alzheimer's Disease, 2011, 26, 201-214.	2.6	68
130	Staging Alzheimer's disease progression with multimodality neuroimaging. Progress in Neurobiology, 2011, 95, 535-546.	5.7	68
131	Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2002, 17, 950-955.	2.7	67
132	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. Journal of Alzheimer's Disease, 2015, 44, 815-826.	2.6	67
133	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 214-227.	3.1	67
134	Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. The Cochrane Library, 2020, 3, CD009628.	2.8	67
135	Reactivity of Cortical Alpha Rhythms to Eye Opening in Mild Cognitive Impairment and Alzheimer's Disease: an EEG Study. Journal of Alzheimer's Disease, 2011, 22, 1047-1064.	2.6	66
136	Whiteâ€matter lesions along the cholinergic tracts are related to cortical sources of EEG rhythms in amnesic mild cognitive impairment. Human Brain Mapping, 2009, 30, 1431-1443.	3.6	64
137	Microbiota and neurodegenerative diseases. Current Opinion in Neurology, 2017, 30, 630-638.	3.6	64
138	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
139	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.8	64
140	Drug Treatment of REM Sleep Behavior Disorders in Dementia With Lewy Bodies. International Psychogeriatrics, 2003, 15, 377-383.	1.0	63
141	Abnormal hippocampal shape in offenders with psychopathy. Human Brain Mapping, 2010, 31, 438-447.	3.6	63
142	Global Functional Coupling of Resting EEG Rhythms is Related to White-Matter Lesions Along the Cholinergic Tracts in Subjects with Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 19, 859-871.	2.6	63
143	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. NeuroImage, 2015, 123, 149-164.	4.2	63
144	White matter lesions in the elderly: Pathophysiological hypothesis on the effect on brain plasticity and reserve. Journal of the Neurological Sciences, 2008, 273, 3-9.	0.6	62

#	Article	IF	CITATIONS
145	Prevention trials in Alzheimer's disease: An EU-US task force report. Progress in Neurobiology, 2011, 95, 594-600.	5.7	62
146	Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage. Neurobiology of Aging, 2012, 33, 1023-1033.	3.1	61
147	Cortical sources of resting state electroencephalographic alpha rhythms deteriorate across time in subjects with amnesic mild cognitive impairment. Neurobiology of Aging, 2014, 35, 130-142.	3.1	61
148	Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADCâ€ADNI HarmonizedÂHippocampal Segmentation Protocol. Alzheimer's and Dementia, 2015, 11, 139-150.	0.8	61
149	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiology of Aging, 2018, 65, 18-40.	3.1	61
150	Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI). Experimental Gerontology, 2009, 44, 579-585.	2.8	60
151	Detailed volumetric analysis of the hypothalamus in behavioral variant frontotemporal dementia. Journal of Neurology, 2015, 262, 2635-2642.	3.6	60
152	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	3.1	60
153	Mild Cognitive Deterioration with Subcortical Features: Prevalence, Clinical Characteristics, and Association with Cardiovascular Risk Factors in Community-Dwelling Older Persons (The InCHIANTI) Tj ETQq1 1	0.7 8.4 314	rgଞ୍ଚି୭/Overl <mark>o</mark> c
154	Medial temporal atrophy in early and late-onset Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2004-2012.	3.1	59
155	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	3.1	59
156	Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer's disease subjects. Clinical Neurophysiology, 2007, 118, 1244-1260.	1.5	58
157	Prevalence of the apolipoprotein E Îμ4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
158	Effect of Memantine on Resting State Default Mode Network Activity in Alzheimer's Disease. Drugs and Aging, 2011, 28, 205-217.	2.7	57
159	Increase of Theta/Gamma and Alpha3/Alpha2 Ratio is Associated with Amygdalo-Hippocampal Complex Atrophy. Journal of Alzheimer's Disease, 2009, 17, 349-357.	2.6	56
160	Virtual imaging laboratories for marker discovery in neurodegenerative diseases. Nature Reviews Neurology, 2011, 7, 429-438.	10.1	56
161	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
162	Validity of Direct Assessment of Functional Status as a tool for measuring Alzheimer's disease severity. Age and Ageing, 1998, 27, 615-622.	1.6	55

#	Article	IF	CITATIONS
163	Grid infrastructures for computational neuroscience: the neuGRID example. Future Neurology, 2009, 4, 703-722.	0.5	55
164	Brain volumes in healthy adults aged 40 years and over: a voxel-based morphometry study. Aging Clinical and Experimental Research, 2005, 17, 329-336.	2.9	54
165	Brain SPECT in subtypes of mild cognitive impairment. Journal of Neurology, 2008, 255, 1344-1353.	3.6	54
166	Depressive symptoms combined with dementia affect 12â€months survival in elderly patients after rehabilitation postâ€hip fracture surgery. International Journal of Geriatric Psychiatry, 2008, 23, 1073-1077.	2.7	54
167	Disentangling normal aging from Alzheimer's disease in structural magnetic resonance images. Neurobiology of Aging, 2015, 36, S42-S52.	3.1	54
168	White matter vascular lesions are related to parietalâ€ŧoâ€frontal coupling of EEG rhythms in mild cognitive impairment. Human Brain Mapping, 2008, 29, 1355-1367.	3.6	53
169	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. Neurobiology of Aging, 2016, 48, 122-134.	3.1	53
170	Head-to-Head Comparison of Two Popular Cortical Thickness Extraction Algorithms: A Cross-Sectional and Longitudinal Study. PLoS ONE, 2015, 10, e0117692.	2.5	53
171	Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study. Neurobiology of Aging, 2013, 34, 1728-1739.	3.1	52
172	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.8	51
173	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. Frontiers in Neuroscience, 2016, 10, 604.	2.8	51
174	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.1	51
175	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. Journal of Neurology, 2013, 260, 640-650.	3.6	50
176	How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer's disease? A review of neuroimaging studies. Neurobiology of Aging, 2000, 21, 293-300.	3.1	49
177	White-matter vascular lesions correlate with alpha EEG sources in mild cognitive impairment. Neuropsychologia, 2008, 46, 1707-1720.	1.6	49
178	Morphological Hippocampal Markers for Automated Detection of Alzheimer's Disease and Mild Cognitive Impairment Converters in Magnetic Resonance Images. Journal of Alzheimer's Disease, 2009, 17, 643-659.	2.6	48
179	Resting State Cortical Electroencephalographic Rhythms and White Matter Vascular Lesions in Subjects with Alzheimer's Disease: An Italian Multicenter Study. Journal of Alzheimer's Disease, 2011, 26, 331-346.	2.6	48
180	The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of Aging, 2012, 33, 201.e1-201.e8.	3.1	48

#	Article	IF	CITATIONS
181	Pattern of structural and functional brain abnormalities in asymptomatic granulin mutation carriers. Alzheimer's and Dementia, 2014, 10, S354-S363.e1.	0.8	48
182	Operationalizing protocol differences for EADCâ€ADNI manual hippocampal segmentation. Alzheimer's and Dementia, 2015, 11, 184-194.	0.8	48
183	Neuroharmony: A new tool for harmonizing volumetric MRI data from unseen scanners. NeuroImage, 2020, 220, 117127.	4.2	48
184	Apolipoprotein E ε4 Allele in Alzheimer's Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 1994, 5, 240-242.	1.5	47
185	The Predementia Diagnosis of Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2004, 18, 51-53.	1.3	47
186	Metabolic patterns across core features in dementia with lewy bodies. Annals of Neurology, 2019, 85, 715-725.	5.3	47
187	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
188	Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. Alzheimer's and Dementia, 2012, 8, 445-452.	0.8	46
189	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study. Journal of Alzheimer's Disease, 2017, 59, 339-358.	2.6	45
190	Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer's and Parkinson's diseases. Clinical Neurophysiology, 2018, 129, 766-782.	1.5	45
191	Corticobasal Degeneration: Neuropsychological Assessment and Dopamine D ₂ Receptor SPECT Analysis. European Neurology, 1995, 35, 50-54.	1.4	44
192	EEG upper/low alpha frequency power ratio relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment. Frontiers in Aging Neuroscience, 2013, 5, 63.	3.4	44
193	Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation. Journal of Alzheimer's Disease, 2018, 65, 221-230.	2.6	44
194	Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. Psychiatry Research - Neuroimaging, 2011, 193, 182-190.	1.8	43
195	Structural brain features of borderline personality and bipolar disorders. Psychiatry Research - Neuroimaging, 2013, 213, 83-91.	1.8	43
196	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. Alzheimer's and Dementia, 2015, 11, 850-859.	0.8	43
197	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of diseaseâ€modifying therapies. Alzheimer's and Dementia, 2020, 16, 1457-1468.	0.8	43
198	Reality Orientation Therapy to delay outcomes of progression in patients with dementia. A retrospective study. Clinical Rehabilitation, 2001, 15, 471-478.	2.2	42

#	Article	IF	CITATIONS
199	Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia. Journal of Alzheimer's Disease, 2009, 16, 235-270.	2.6	42
200	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2009, 17, 761-772.	2.6	42
201	Moderate to severe depressive symptoms and rehabilitation outcome in older adults with hip fracture. International Journal of Geriatric Psychiatry, 2011, 26, 1136-1143.	2.7	42
202	Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use. International Psychogeriatrics, 2011, 23, 1191-1196.	1.0	42
203	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. NeuroImage: Clinical, 2019, 24, 101954.	2.7	42
204	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Movement Disorders, 2020, 35, 595-605.	3.9	42
205	Principal Lifetime Occupation and Sleep Quality in the Elderly. Gerontology, 1996, 42, 163-169.	2.8	41
206	Imaging the Alzheimer Brain. Journal of Alzheimer's Disease, 2011, 26, 1-27.	2.6	41
207	Stability of clinical condition in mild cognitive impairment is related to cortical sources of alpha rhythms: An electroencephalographic study. Human Brain Mapping, 2011, 32, 1916-1931.	3.6	41
208	Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dementia and Geriatric Cognitive Disorders, 2013, 36, 1-19.	1.5	41
209	Harmonized benchmark labels of the hippocampus on magnetic resonance: The EADCâ€ADNI project. Alzheimer's and Dementia, 2015, 11, 151.	0.8	41
210	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 563-584.	6.4	41
211	Alzheimer's disease-associated disability: An ICF approach. Disability and Rehabilitation, 2005, 27, 1405-1413.	1.8	40
212	Mapping the Structural Brain Changes in Alzheimer's Disease: The Independent Contribution of Two Imaging Modalities. Journal of Alzheimer's Disease, 2011, 26, 263-274.	2.6	40
213	Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease. Current Alzheimer Research, 2020, 17, 112-125.	1.4	40
214	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.		39
215	The biomarker-based diagnosis of Alzheimer's disease. 1—ethical and societal issues. Neurobiology of Aging, 2017, 52, 132-140.	3.1	39
216	Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. Psychiatry Research - Neuroimaging, 2011, 192, 77-83.	1.8	38

#	Article	IF	CITATIONS
217	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. Human Brain Mapping, 2016, 37, 2114-2132.	3.6	38
218	The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology. Neurobiology of Aging, 2017, 52, 141-152.	3.1	38
219	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. NeuroImage, 2020, 218, 116932.	4.2	38
220	Blunted reduction in night-time blood pressure is associated with cognitive deterioration in subjects with long-standing hypertension. Blood Pressure Monitoring, 2004, 9, 71-76.	0.8	37
221	Clinical Instability as a Predictor ofÂNegative Outcomes Among Elderly Patients Admitted toÂa Rehabilitation Ward. Journal of the American Medical Directors Association, 2010, 11, 443-448.	2.5	37
222	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
223	Using normative modelling to detect disease progression in mild cognitive impairment and Alzheimer's disease in a cross-sectional multi-cohort study. Scientific Reports, 2021, 11, 15746.	3.3	37
224	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services—part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171.	6.2	37
225	Validation Study of a CT-Based Weighted Rating Scale for Subcortical Ischemic Vascular Disease in Patients with Mild Cognitive Deterioration. European Neurology, 2003, 49, 193-209.	1.4	36
226	Brain perfusion correlates of medial temporal lobe atrophy and white matter hyperintensities in mild cognitive impairment. Journal of Neurology, 2007, 254, 1000-1008.	3.6	36
227	Regional atrophy of transcallosal prefrontal connections in cognitively normal <i>APOE</i> ϵ4 carriers. Journal of Magnetic Resonance Imaging, 2009, 29, 1021-1026.	3.4	36
228	Comparison of Bioinformatics Pipelines and Operating Systems for the Analyses of 16S rRNA Gene Amplicon Sequences in Human Fecal Samples. Frontiers in Microbiology, 2020, 11, 1262.	3.5	36
229	ANOREXIA AS AN INDEPENDENT PREDICTOR OF MORTALITY. Journal of the American Geriatrics Society, 2005, 53, 354-355.	2.6	35
230	Aging. Neurological Sciences, 2008, 29, 296-300.	1.9	35
231	Erratum to "A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis― BioMed Research International, 2014, 2014, 1-1.	1.9	35
232	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
233	Distinct cerebrospinal fluid amyloidâ€beta peptide signatures in cognitive decline associated with <scp>A</scp> lzheimer's disease and schizophrenia. Electrophoresis, 2012, 33, 3738-3744.	2.4	34
234	Atypical nucleus accumbens morphology in psychopathy: Another limbic piece in the puzzle. International Journal of Law and Psychiatry, 2013, 36, 157-167.	0.9	34

#	Article	IF	CITATIONS
235	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite <scp>E</scp> uropean 3T study on healthy elderly. Human Brain Mapping, 2015, 36, 3516-3527.	3.6	34
236	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
237	Association of Apolipoprotein E E4 With Vascular Dementia. JAMA - Journal of the American Medical Association, 1994, 271, 1317.	7.4	33
238	Predictive Role of Single Diseases and Their Combination on Recovery of Balance and Gait in Disabled Elderly Patients. Journal of the American Medical Directors Association, 2006, 7, 208-211.	2.5	33
239	Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. European Journal of Human Genetics, 2006, 14, 443-449.	2.8	33
240	Amnestic MCI future clinical status prediction using baseline MRI features. Neurobiology of Aging, 2010, 31, 1606-1617.	3.1	33
241	Anatomical Substrate and Scalp EEG Markers are Correlated in Subjects with Cognitive Impairment and Alzheimer's Disease. Frontiers in Psychiatry, 2011, 1, 152.	2.6	33
242	The European DTI Study on Dementia — A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. NeuroImage, 2017, 144, 305-308.	4.2	33
243	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.8	33
244	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2019, 77, 112-127.	3.1	33
245	Abnormalities in functional connectivity in borderline personality disorder: Correlations with metacognition and emotion dysregulation. Psychiatry Research - Neuroimaging, 2019, 283, 118-124.	1.8	33
246	Subcortical Vascular Lesions Predict Functional Recovery After Rehabilitation in Patients with Lâ€Dopa Refractory Parkinsonism. Journal of the American Geriatrics Society, 2004, 52, 252-256.	2.6	32
247	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. Alzheimer's and Dementia, 2012, 8, 520-527.	0.8	32
248	Neurophysiological Assessment of Alzheimer's Disease Individuals by a Single Electroencephalographic Marker. Journal of Alzheimer's Disease, 2015, 49, 159-177.	2.6	32
249	The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. Aging Clinical and Experimental Research, 2009, 21, 266-276.	2.9	31
250	Volumetric and topographic differences in hippocampal subdivisions in borderline personality and bipolar disorders. Psychiatry Research - Neuroimaging, 2012, 203, 132-138.	1.8	31
251	Re-aligning scientific and lay narratives of Alzheimer's disease. Lancet Neurology, The, 2019, 18, 918-919.	10.2	31
252	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.8	31

#	Article	IF	CITATIONS
253	Computed Tomography in the Detection of the Vascular Component in Dementia. Gerontology, 1995, 41, 121-128.	2.8	30
254	Cardiac Autonomic Dysfunction Is Associated With White Matter Lesions in Patients With Mild Cognitive Impairment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 1312-1315.	3.6	30
255	Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer's disease. Clinical Neurophysiology, 2009, 120, 709-718.	1.5	30
256	Revised criteria for Alzheimer's disease: what are the lessons for clinicians?. Lancet Neurology, The, 2011, 10, 598-601.	10.2	30
257	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30
258	Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: why and how—a decision-making support from the working group on â€~hypertension and the brain' of the European Society of Hypertension and from the European Geriatric Medicine Society. Journal of Hypertension, 2021, 39, 90-100.	0.5	30
259	Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements. Clinical Neurophysiology, 2021, 132, 232-245.	1.5	30
260	Brain investigation and brain conceptualization. Functional Neurology, 2013, 28, 175-90.	1.3	30
261	Treatment of Alzheimer's disease with acetylcholinesterase inhibitors: bridging the gap between evidence and practice. Journal of Neurology, 2001, 248, 551-557.	3.6	29
262	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
263	Predictors of cognitive improvement after reality orientation in Alzheimer's disease. Age and Ageing, 2002, 31, 193-196.	1.6	28
264	Digital biomarkerâ€based individualized prognosis for people at risk of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12073.	2.4	28
265	Alzheimer's CSF markers in older schizophrenia patients. International Journal of Geriatric Psychiatry, 2011, 26, 640-648.	2.7	27
266	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	3.1	27
267	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. NeuroImage, 2017, 163, 106-114.	4.2	27
268	Global Functional Coupling of Resting EEG Rhythms is Abnormal in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Psychophysiology, 2009, 23, 224-234.	0.7	27
269	Assessment of alcohol consumption and alcoholism in the elderly. Alcohol, 1994, 11, 513-516.	1.7	26
270	Regional Brain Atrophy in Patients With Mild Alzheimer's Disease and Delusions. International Psychogeriatrics, 2002, 14, 365-378.	1.0	26

#	Article	IF	CITATIONS
271	Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. Neurobiology of Aging, 2019, 73, 9-20.	3.1	26
272	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6. Alzheimer's Research and Therapy, 2021, 13, 168.	6.2	26
273	Alzheimer's Disease Neuroimaging Initiative in Europe. , 2010, 6, 280-285.		25
274	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. Neurobiology of Aging, 2015, 36, 776-788.	3.1	25
275	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	1.9	25
276	Association between subcortical vascular disease on CT and neuropathological findings. International Journal of Geriatric Psychiatry, 2004, 19, 690-695.	2.7	24
277	Does cognitive performance affect physical therapy regimen after hip fracture surgery?. Aging Clinical and Experimental Research, 2007, 19, 119-124.	2.9	24
278	Increase of theta frequency is associated with reduction in regional cerebral blood flow only in subjects with mild cognitive impairment with higher upper alpha/low alpha EEG frequency power ratio. Frontiers in Behavioral Neuroscience, 2013, 7, 188.	2.0	24
279	Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?. Alzheimer's Research and Therapy, 2014, 6, 51.	6.2	24
280	HarP: The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation. A standard of reference from a global working group. Alzheimer's and Dementia, 2015, 11, 107-110.	0.8	24
281	Automated hippocampal segmentation in 3D MRI using random undersampling with boosting algorithm. Pattern Analysis and Applications, 2016, 19, 579-591.	4.6	24
282	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. Neurobiology of Aging, 2020, 91, 88-111.	3.1	24
283	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
284	Increasing Hippocampal Atrophy and Cerebrovascular Damage Is Differently Associated With Functional Cortical Coupling in MCI Patients. Alzheimer Disease and Associated Disorders, 2009, 23, 323-332.	1.3	23
285	Clinical and medial temporal features in a family with mood disorders. Neuroscience Letters, 2010, 468, 93-97.	2.1	23
286	Establishing Magnetic Resonance Images Orientation for the EADCâ€ADNI Manual Hippocampal Segmentation Protocol. Journal of Neuroimaging, 2014, 24, 509-514.	2.0	23
287	Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. Neurobiology of Aging, 2017, 52, 119-131.	3.1	23
288	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	6.4	23

#	Article	IF	CITATIONS
289	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.8	23
290	Mood improvement in elderly women after in-hospital physical rehabilitation. Archives of Physical Medicine and Rehabilitation, 1996, 77, 346-349.	0.9	22
291	Cortical Networks Generating Movement-Related EEG Rhythms in Alzheimer's Disease: An EEG Coherence Study Behavioral Neuroscience, 2004, 118, 698-706.	1.2	22
292	Neuroimaging outcomes in clinical trials in Alzheimer's disease. Journal of Nutrition, Health and Aging, 2009, 13, 209-212.	3.3	22
293	Diagnosis Disclosure of Prodromal Alzheimer Disease-Ethical Analysis of Two Cases. Canadian Journal of Neurological Sciences, 2010, 37, 67-75.	0.5	22
294	Prevalence of Aging-Associated Cognitive Decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on Epidemiology of Alzheimer's disease (IPREA). Aging Clinical and Experimental Research, 2010, 22, 440-449.	2.9	22
295	Biomarker trajectories across stages of Alzheimer disease. Nature Reviews Neurology, 2012, 8, 299-300.	10.1	22
296	The Italian Alzheimer's Disease Neuroimaging Initiative (I-ADNI): Validation of Structural MR Imaging. Journal of Alzheimer's Disease, 2014, 40, 941-952.	2.6	22
297	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.	1.4	22
298	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	6.4	22
299	Breaking the diagnosis of dementia. Lancet Neurology, The, 2004, 3, 124-128.	10.2	21
300	Cognitive rehabilitation for severe dementia: Critical observations for better use of existing knowledge. Mechanisms of Ageing and Development, 2006, 127, 166-172.	4.6	21
301	Analysis of Grey Matter in Thalamus and Basal Ganglia Based on EEG α3∫α2 Frequency Ratio Reveals Specific Changes in Subjects with Mild Cognitive Impairment. ASN Neuro, 2012, 4, AN20120058.	2.7	21
302	Low-Dose Radiation Therapy: A New Treatment Strategy for Alzheimer's Disease?. Journal of Alzheimer's Disease, 2020, 74, 411-419.	2.6	21
303	Dementia risk communication. A user manual for Brain Health Services—part 3 of 6. Alzheimer's Research and Therapy, 2021, 13, 170.	6.2	21
304	Napping in the Elderly and Its Association with Night Sleep and Psychological Status. International Psychogeriatrics, 1996, 8, 477-487.	1.0	20
305	Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. Psychiatry Research - Neuroimaging, 2016, 252, 26-35.	1.8	20
306	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.8	20

#	Article	IF	CITATIONS
307	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	3.3	20
308	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	3.4	20
309	Clinical and Neuropsychological Features Associated with Structural Imaging Patterns in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 23, 175-183.	1.5	19
310	Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment. Biomarkers in Medicine, 2012, 6, 365-368.	1.4	19
311	Hippocampal atrophy in people with memory deficits: results from the population-based IPREA study. International Psychogeriatrics, 2014, 26, 1067-1081.	1.0	19
312	Hippocampal and Amygdalar Local Structural Differences in Elderly Patients with Schizophrenia. American Journal of Geriatric Psychiatry, 2015, 23, 47-58.	1.2	19
313	Assessing FDC-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486.	6.4	19
314	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
315	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2200-2211.	6.4	19
316	Treatment by low-dose brain radiation therapy improves memory performances without changes of the amyloid load in the TgF344-AD rat model. Neurobiology of Aging, 2021, 103, 117-127.	3.1	19
317	A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages. Journal of Personalized Medicine, 2021, 11, 14.	2.5	19
318	In Vivo Neuropathology of Cortical Changes in Elderly Persons with Schizophrenia. Biological Psychiatry, 2009, 66, 578-585.	1.3	18
319	Cortical Changes in Incipient Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1339-1349.	2.6	18
320	A Score to Predict the Development of Adverse Clinical Events after Transition from Acute Hospital Wards to Post–Acute Care Settings. Rejuvenation Research, 2012, 15, 553-563.	1.8	18
321	Norms for Imaging Markers of Brain Reserve. Journal of Alzheimer's Disease, 2012, 31, 623-633.	2.6	18
322	Biomarkers for Alzheimer's: the sequel of an original model. Lancet Neurology, The, 2013, 12, 126-128.	10.2	18
323	Biomarker-based diagnosis of mild cognitive impairment due to Alzheimerââ,¬â,,¢s disease: how and what to tell. A kickstart to an ethical discussion. Frontiers in Aging Neuroscience, 2014, 6, 41.	3.4	18
324	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. Journal of Alzheimer's Disease, 2016, 51, 277-291.	2.6	18

#	Article	IF	CITATIONS
325	Association of postoperative delirium with markers of neurodegeneration and brain amyloidosis: a pilot study. Neurobiology of Aging, 2018, 61, 93-101.	3.1	18
326	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	6.4	18
327	The Added Value of Neuropsychologic Tests and Structural Imaging for the Etiologic Diagnosis of Dementia in Italian Expert Centers. Alzheimer Disease and Associated Disorders, 2008, 22, 309-320.	1.3	17
328	Alzheimer's Disease Neuroimaging Initiative special issue. Neurobiology of Aging, 2010, 31, 1259-1262.	3.1	17
329	Manual segmentation qualification platform for the EADCâ€ADNI harmonized protocol for hippocampal segmentation project. Alzheimer's and Dementia, 2015, 11, 161-174.	0.8	17
330	Age at onset reveals different functional connectivity abnormalities in prodromal Alzheimer's disease. Brain Imaging and Behavior, 2020, 14, 2594-2605.	2.1	17
331	Mapping the Effects of Aβ 1 â^' 42 Levels on the Longitudinal Changes in Healthy Aging: Hierarchical Modeling Based on Stationary Velocity Fields. Lecture Notes in Computer Science, 2011, 14, 663-670.	1.3	17
332	DEMENTIA DOES NOT PREVENT THE RESTORATION OF SAFE GAIT AFTER HIP FRACTURE. Journal of the American Geriatrics Society, 1997, 45, 1406-1407.	2.6	16
333	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. Alzheimer's and Dementia, 2014, 10, 456-467.	0.8	16
334	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	3.4	16
335	Hybrid PET-MRI in Alzheimer's Disease Research. Methods in Molecular Biology, 2018, 1750, 185-200.	0.9	16
336	Low-Dose Radiation Therapy Reduces Amyloid Load in Young 3xTg-AD Mice. Journal of Alzheimer's Disease, 2022, 86, 641-653.	2.6	16
337	Subcortical Vascular Lesions Predict Falls at 12 Months in Elderly Patients Discharged From a Rehabilitation Ward. Archives of Physical Medicine and Rehabilitation, 2008, 89, 1522-1527.	0.9	15
338	Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloidâ€₽ET. Alzheimer's and Dementia, 2018, 14, 1088-1098.	0.8	15
339	Inter-Cohort Validation of SuStaIn Model for Alzheimer's Disease. Frontiers in Big Data, 2021, 4, 661110.	2.9	15
340	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12314.	2.4	15
341	The Management of Adverse Clinical Events in Nursing Homes: A 1-Year Survey Study. Journal of the American Geriatrics Society, 2001, 49, 915-925.	2.6	14
342	Validation Study of the Three-Objects-Three-Places Test: A Screening Test for Alzheimer's Disease. Experimental Aging Research, 2006, 32, 395-410.	1.2	14

#	Article	IF	CITATIONS
343	Quantitative evaluation of Alzheimer's disease. Expert Review of Medical Devices, 2009, 6, 569-588.	2.8	14
344	Cortical sources of EEG rhythms in congestive heart failure and Alzheimer's disease. International Journal of Psychophysiology, 2012, 86, 98-107.	1.0	14
345	The habenula: an under-recognised area of importance in frontotemporal dementia?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 910-912.	1.9	14
346	Resting-state electroencephalographic delta rhythms may reflect global cortical arousal in healthy old seniors and patients with Alzheimer's disease dementia. International Journal of Psychophysiology, 2020, 158, 259-270.	1.0	14
347	Abnormalities of Cortical Sources of Resting State Alpha Electroencephalographic Rhythms are Related to Education Attainment in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. Cerebral Cortex, 2021, 31, 2220-2237.	2.9	14
348	Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI. Alzheimer Disease and Associated Disorders, 2015, 29, 101-109.	1.3	14
349	Societal and equity challenges for Brain Health Services. A user manual for Brain Health Services—part 6 of 6. Alzheimer's Research and Therapy, 2021, 13, 173.	6.2	14
350	Psychic correlates of sleep symptoms in the elderly. International Journal of Geriatric Psychiatry, 1992, 7, 891-898.	2.7	13
351	CHANGE IN FUNCTIONAL STATUS DURING HOSPITALIZATION IN OLDER ADULTS: A GERIATRIC CONCEPT OF FRAILTY. Journal of the American Geriatrics Society, 2000, 48, 1024-1025.	2.6	13
352	Preliminary Evidence of Validity of the Revised Criteria for Alzheimer Disease Diagnosis. Alzheimer Disease and Associated Disorders, 2010, 24, 108-114.	1.3	13
353	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	2.6	13
354	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.8	13
355	Clinical characteristics of frontotemporal patients with symmetric brain atrophy. European Archives of Psychiatry and Clinical Neuroscience, 2002, 252, 235-239.	3.2	12
356	Pathological Validation of a CT-Based Scale for Subcortical Vascular Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 61-66.	1.5	12
357	Drug prescription in mild cognitive impairment: the physicians' perspective in Italy. International Journal of Geriatric Psychiatry, 2006, 21, 1071-1077.	2.7	12
358	Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both a-synucleinopathy and tauopathy. Neuropsychiatric Disease and Treatment, 2014, 10, 1003.	2.2	12
359	The SIENA/FSL whole brain atrophy algorithm is no more reproducible at 3 T than 1.5 T for Alzheimer× ³ s disease. Psychiatry Research - Neuroimaging, 2014, 224, 14-21.	1.8	12
360	Medial temporal lobe atrophy and posterior atrophy scales normative values. NeuroImage: Clinical, 2019, 24, 101936.	2.7	12

#	Article	IF	CITATIONS
361	Intepirdine as adjunctive therapy to donepezil for mildâ€toâ€moderate Alzheimer's disease: A randomized, placeboâ€controlled, phase 3 clinical trial (MINDSET). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12136.	3.7	12
362	HOXA1 A218G Polymorphism is Associated with Smaller Cerebellar Volume in Healthy Humans. Journal of Neuroimaging, 2009, 19, 353-358.	2.0	11
363	H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers. European Journal of Human Genetics, 2009, 17, 287-294.	2.8	11
364	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	3.1	11
365	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. Clinical Neurophysiology, 2020, 131, 2716-2731.	1.5	11
366	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2086-2096.	6.4	11
367	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases. Neurobiology of Aging, 2022, 115, 88-108.	3.1	11
368	Detection of the Presenilin 1 COOH-Terminal Fragment in the Extracellular Compartment: A Release Enhanced by Apoptosis. Experimental Cell Research, 2001, 269, 256-265.	2.6	10
369	Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data. Brain Communications, 2021, 3, fcab091.	3.3	10
370	Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts. Frontiers in Neurology, 2020, 11, 1021.	2.4	10
371	How fast will it go, doc?. Neurology, 2008, 70, 2194-2195.	1.1	9
372	Random Forest Classification for Hippocampal Segmentation in 3D MR Images. , 2013, , .		9
373	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. Neurobiology of Aging, 2021, 103, 78-97.	3.1	9
374	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	7.9	9
375	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. NeuroImage: Clinical, 2022, 35, 103106.	2.7	9
376	The Diagnosis of Alzheimer Disease Before It Is Alzheimer Dementia. Archives of Neurology, 2003, 60, 1023.	4.5	8
377	Effect of the Xbal polymorphism of estrogen receptor alpha on postmenopausal gray matter. Neuroscience Letters, 2008, 434, 304-309.	2.1	8
378	Multi-Center Comparison of Medial Temporal Atrophy in Patients with Alzheimer's Disease – Data from the ICTUS Study. Dementia and Geriatric Cognitive Disorders, 2008, 26, 314-322.	1.5	8

#	Article	IF	CITATIONS
379	Association of Blood Pressure and Genetic Background With White Matter Lesions in Patients With Mild Cognitive Impairment. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 510-517.	3.6	8
380	PET and 18F ligands in the diagnosis of Alzheimer's disease. Lancet Neurology, The, 2011, 10, 397-399.	10.2	8
381	Resting State Cortical Electroencephalographic Rhythms in Covert Hepatic Encephalopathy and Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 707-725.	2.6	8
382	The in vivo topography of cortical changes in healthy aging and prodromal Alzheimer's disease. Supplements To Clinical Neurophysiology, 2013, 62, 67-80.	2.1	8
383	Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimerââ,¬â"¢s disease. Frontiers in Aging Neuroscience, 2014, 6, 179.	3.4	8
384	The COURAGE Built Environment Outdoor Checklist: An Objective Built Environment Instrument to Investigate the Impact of the Environment on Health and Disability. Clinical Psychology and Psychotherapy, 2014, 21, 204-214.	2.7	8
385	Impact of alcohol consumption in healthy adults: A magnetic resonance imaging investigation. Psychiatry Research - Neuroimaging, 2014, 224, 96-103.	1.8	8
386	Clinical trial design of serious gaming in mild cognitive impairment. Frontiers in Aging Neuroscience, 2015, 7, 26.	3.4	8
387	Biomarkers for Alzheimer's disease: a controversial topic. Lancet Neurology, The, 2015, 14, 781-783.	10.2	8
388	Re: Cranial irradiation significantly reduces beta amyloid plaques in the brain and improves cognition in a murine model of Alzheimer's Disease (AD). Radiotherapy and Oncology, 2016, 118, 577-578.	0.6	8
389	Abnormalities of Cortical Sources of Resting State Delta Electroencephalographic Rhythms Are Related to Epileptiform Activity in Patients With Amnesic Mild Cognitive Impairment Not Due to Alzheimer's Disease. Frontiers in Neurology, 2020, 11, 514136.	2.4	8
390	Rationale, Design, and Methodology of a Prospective Cohort Study for Coping with Behavioral and Psychological Symptoms of Dementia: The RECage Project1. Journal of Alzheimer's Disease, 2021, 80, 1613-1627.	2.6	8
391	Resting State Alpha Electroencephalographic Rhythms Are Differently Related to Aging in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 82, 1085-1114.	2.6	8
392	Alzheimer's Disease Biomarkers in Idiopathic Normal Pressure Hydrocephalus: Linking Functional Connectivity and Clinical Outcome. Journal of Alzheimer's Disease, 2021, 83, 1-12.	2.6	8
393	Resting State Alpha Electroencephalographic Rhythms Are Affected by Sex in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment: A Retrospective and Exploratory Study. Cerebral Cortex, 2022, 32, 2197-2215.	2.9	8
394	WHO ARE THE OLDER PATIENTS FAILING TO RECOVER MOBILITY AFTER REHABILITATION?. Journal of the American Geriatrics Society, 1997, 45, 250-252.	2.6	7
395	Feeding tube use in Italian nursing homes: The role of cultural factors. Journal of the American Medical Directors Association, 2005, 6, 87-88.	2.5	7
396	Understanding information on clinical trials by persons with Alzheimer's dementia. A pilot study. Aging Clinical and Experimental Research, 2009, 21, 158-166.	2.9	7

#	Article	IF	CITATIONS
397	Cauda equina syndrome caused by lumbosacral epidural lipomatosis. A case report. Clinical Neurology and Neurosurgery, 2013, 115, 1549-1551.	1.4	7
398	The Association Between APOE ε4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	2.6	7
399	Neurology—the next 10 years. Nature Reviews Neurology, 2015, 11, 658-664.	10.1	7
400	EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment Current Alzheimer Research, 2014, 11, 192-199.	1.4	7
401	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
402	Charles Bonnet Syndrome and GABAergic Drugs—A Case Report. Journal of the American Geriatrics Society, 2004, 52, 646-647.	2.6	6
403	Prescription and choice of diagnostic imaging by physician specialty in Alzheimer's Centers (Unità di) Tj ETQo 14-19.	1 1 0.784 2.9	1314 rgBT / 6
404	Subcortical vascular dementia exists!. Neurology, 2011, 77, 12-13.	1.1	6
405	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?. Neurodegenerative Diseases, 2016, 16, 111-117.	1.4	6
406	Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study. Aging Clinical and Experimental Research, 2020, 32, 817-826.	2.9	6
407	Description of a European memory clinic cohort undergoing amyloidâ€PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.8	6
408	The relationship between biological and environmental determinants of delusions in mild Alzheimer's disease patients. International Journal of Geriatric Psychiatry, 2002, 17, 687-688.	2.7	5
409	Physical complaints do not decrease linearly with increasing cognitive impairment. International Journal of Geriatric Psychiatry, 2002, 17, 1073-1075.	2.7	5
410	Tau missing from CSF. Journal of Neurology, 2007, 254, 107-109.	3.6	5
411	Traceability and Provenance in Big Data Medical Systems. , 2015, , .		5
412	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	2.6	5
413	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A Europeanâ€DLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.8	5
414	Molecular imaging and fluid biomarkers of Alzheimer's disease neuropathology: an opportunity for integrated diagnostics. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2067-2069.	6.4	5

#	Article	IF	CITATIONS
415	Brain Metabolism and Amyloid Load in Individuals With Subjective Cognitive Decline or Pre–Mild Cognitive Impairment. Neurology, 2022, 99, .	1.1	5
416	Differential associations of Head and Body Symptoms with depression and physical comorbidity in patients with cognitive impairment. International Journal of Geriatric Psychiatry, 2004, 19, 209-215.	2.7	4
417	ARIA from off-key operas?. Lancet Neurology, The, 2012, 11, 207-208.	10.2	4
418	[P4–157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.8	4
419	Education-Adjusted Normality Thresholds for FDG-PET in the Diagnosis of Alzheimer Disease. Neurodegenerative Diseases, 2018, 18, 120-126.	1.4	4
420	Norms for Automatic Estimation of Hippocampal Atrophy and a Step Forward for Applicability to the Italian Population. Frontiers in Neuroscience, 2021, 15, 656808.	2.8	4
421	Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnestic Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2021, 82, 1797-1808.	2.6	4
422	The Heterogeneity and Natural History of Mild Cognitive Impairment. Archives of Neurology, 2005, 62, 163.	4.5	3
423	Dementia: important advances in research in 2006. Lancet Neurology, The, 2007, 6, 4-5.	10.2	3
424	Imaging of amyloid comes of age. Lancet Neurology, The, 2008, 7, 114-115.	10.2	3
425	The specificity of amyloid imaging in the diagnosis of neurodegenerative diseases. Neurobiology of Aging, 2012, 33, 1021-1022.	3.1	3
426	Alzheimer's disease biomarker development: a call to funding bodies. Neurobiology of Aging, 2017, 52, 117-118.	3.1	3
427	One step towards dementia prevention. Lancet Neurology, The, 2018, 17, 294-295.	10.2	3
428	Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use. Clinical and Translational Imaging, 2018, 6, 471-482.	2.1	3
429	Cortical Superficial Siderosis: A Descriptive Analysis in a Memory Clinic Population. Journal of Alzheimer's Disease, 2020, 73, 1467-1479.	2.6	3
430	Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer's Disease and Neurodegeneration: Old Drugs, New Concerns. Frontiers in Oncology, 2021, 11, 734881.	2.8	3
431	Hippocampal segmentation by Random Forest classification. , 2011, , .		2
432	Primary or secondary prevention for AD: who cares?. Lancet Neurology, The, 2012, 11, 661-662.	10.2	2

#	Article	IF	CITATIONS
433	Brain FDG-PET: clinical use in dementing neurodegenerative conditions. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1467-1469.	6.4	2
434	Improved Reproducibility of Neuroanatomical Definitions through Diffeomorphometry and Complexity Reduction. Lecture Notes in Computer Science, 2014, , 223-230.	1.3	2
435	From patients to disease: the difficult case of Alzheimer's. Lancet Neurology, The, 2022, 21, 105-106.	10.2	2
436	SimulAD: a dynamical model for personalized simulation and disease staging in Alzheimer's disease. Neurobiology of Aging, 2022, 113, 73-83.	3.1	2
437	Alzheimer's Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, , 1-29.	2.6	2
438	THE RELEVANCE OF GENETIC TESTING IN LATEâ€ONSET HUNTINGTON'S DISEASE. Journal of the American Geriatrics Society, 1996, 44, 609-611.	2.6	1
439	Development of a CT-based weighted rating scale for subcortical cerebrovascular disease sensitive to mild clinical symptoms. Journal of the Neurological Sciences, 2002, 203-204, 241-245.	0.6	1
440	Interactive neuroimaging. Lancet Neurology, The, 2008, 7, 204.	10.2	1
441	Manual segmentation certification platform. , 2013, , .		1
442	Analysis Traceability for Biomedical Researchers. , 2014, , .		1
443	[P1–427]: AGEâ€RELATED WHITE MATTER CHANGES SCALE: NORMATIVE DATA ON 1,439 PERSONS. Alzheimer and Dementia, 2017, 13, P443.	' ^{\$} 0.8	1
444	[P2–212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIFâ€AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.8	1
445	ICâ€Pâ€071: THE EFFECT OF APOE ON WHITE MATTER LESIONS. Alzheimer's and Dementia, 2018, 14, P63.	0.8	1
446	Early termination of pivotal trials in Alzheimer's disease—Preserving optimal value for participants and science. Alzheimer's and Dementia, 2022, , .	0.8	1
447	Relationship between resting state alpha electroencephalographic rhythms and aging in cognitively unimpaired seniors and patients with mild cognitive impairment due to Alzheimer's disease and amnestic mild cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.8	1
448	Eva, Her Roommate, and Hitler. Journal of the American Geriatrics Society, 1993, 41, 1155-1155.	2.6	0
449	Cognitive Impairment Modulates the Effect of Depressive Symptoms on Mortality in Elderly People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M1145-M1146.	3.6	0

2.0 0

#	Article	IF	CITATIONS
451	Guest editorial: Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use – ERRATUM. International Psychogeriatrics, 2012, 24, 682-682.	1.0	0
452	A new paradigm for testing AD drugs – neuroimaging biomarkers as surrogate outcomes homologous in animals and humans. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e63-e71.	0.5	0
453	[P2–385]: VISUAL INTERPRETATION OFÂ18Fâ€FLORBETAPIRÂPET/CT IMAGES IN PATIENTS WITH COGNITIVE IMPAIRMENT FROM A MULTICENTER CLINICAL RESEARCH PROJECT (INDIAâ€FBP STUDY): ARE THE DIFFERENT VISUAL CRITERIA OF AMYLOID IMAGE ASSESSMENT SIMILAR IN CLINICAL PRACTICE?. Alzheimer's and Dementia. 2017. 13. P776.	0.8	0
454	[ICâ€₽â€173]: NONâ€INVASIVE BRAIN MODULATION OF ABERRANT NETWORKS IN ALZHEIMER's DISEASE. Alzhei and Dementia, 2017, 13, P129.	mer's 0.8	0
455	[ICâ€Pâ€174]: NETWORKâ€BASED MODULATION OF CEREBRAL PERFUSION AND FUNCTIONAL CONNECTIVITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P130.	0.8	0
456	[P3–199]: ABNORMALITIES OF CORTICAL NEURAL SYNCHRONIZATION MECHANISMS IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S AND PARKINSON'S DISEASES: AN EEG STUDY. Alzheimer's and Dementia, 2017, 13, P1011.	0.8	0
457	[P2–235]: ABNORMALITIES OF RESTING STATE ELECTROENCEPHALOGRAPHIC RHYTHM IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER's, PARKINSON'S AND LEWY BODY DISEASES. Alzheimer's and Dementia, 2017, 13, P701.	0.8	0
458	[P2–357]: POSTOPERATIVE DELIRIUM IS ASSOCIATED WITH MARKERS OF NEURODEGENERATION BUT NO BRAIN AMYLOIDOSIS. Alzheimer's and Dementia, 2017, 13, P760.	0.8	0
459	[P2–421]: DIAGNOSTIC UTILITY OF FDGâ€PET IN DETECTING EARLY SIGNS OF NEURODEGENERATION IN ASYMPTOMATIC SUBJECTS WITH FAMILIAL FORMS OF AD. Alzheimer's and Dementia, 2017, 13, P795.	0.8	Ο
460	[P3–062]: ACROSSâ€SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTIâ€SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P954.	0.8	0
461	[P3–389]: WHEN MEASURING HIPPOCAMPAL ATROPHY, DO THE SEGMENTATION NOISE DISTRIBUTIONS OF METHODS, AS DETERMINED BY THE BACKâ€TOâ€BACK REPRODUCIBILITY, HAVE GAUSSIAN DISTRIBUTIONS?. Alzheimer's and Dementia, 2017, 13, P1109.	0.8	0
462	[P4–226]: BEST COMBINATORIAL LOW OST MARKERS TO PREDICT MCI CONVERSION: AN EMIFâ€AD FEDERATION STUDY. Alzheimer's and Dementia, 2017, 13, P1356.	0.8	0
463	[ICâ€Pâ€129]: DIAGNOSTIC UTILITY OF FDGâ€PET IN DETECTING EARLY SIGNS OF NEURODEGENERATION IN ASYMPTOMATIC SUBJECTS WITH FAMILIAL FORMS OF AD. Alzheimer's and Dementia, 2017, 13, P97.	0.8	0
464	[ICâ€Pâ€132]: WHEN MEASURING HIPPOCAMPAL ATROPHY, DO THE SEGMENTATION NOISE DISTRIBUTIONS OF METHODS, AS DETERMINED BY THE BACK TO BACK REPRODUCIBILITY, HAVE GAUSSIAN DISTRIBUTIONS?. Alzheimer's and Dementia, 2017, 13, P99.	0.8	0
465	[ICâ€Pâ€167]: ACROSSâ€SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTIâ€SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P126.	0.8	0
466	[ICâ€03–04]: WHITE MATTER HYPERINTENSITIES IN GENETIC FRONTOTEMPORAL DEMENTIA: A GENFI STUDY. Alzheimer's and Dementia, 2017, 13, P9.	0.8	0
467	[P1–376]: DIAGNOSTIC UTILITY OF FDGâ€PET IN DIFFERENTIATING ALZHEIMER's DISEASE FROM FRONTOâ€₹EMPORAL LOBAR DEGENERATION. Alzheimer's and Dementia, 2017, 13, P407.	0.8	0
468	[P1–399]: NONâ€INVASIVE BRAIN MODULATION OF ABERRANT NETWORKS IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P425.	0.8	0

#	Article	IF	CITATIONS
469	[P2–334]: NETWORKâ€BASED MODULATION OF CEREBRAL PERFUSION AND FUNCTIONAL CONNECTIVITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.8	0
470	[P4–491]: THE AMYPADâ€ÐX CONTROLLED TRIAL ON THE DIAGNOSTIC VALUE OF AMYLOID PET. Alzheimer's and Dementia, 2017, 13, P1523.	0.8	0
471	P4â€064: THE EFFECT OF APOE ON WHITE MATTER LESIONS. Alzheimer's and Dementia, 2018, 14, P1457.	0.8	0
472	P1â€395: FUNCTIONAL NETWORK CONNECTIVITY CHANGES IN EARLY AND LATE ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P453.	0.8	0
473	ICâ€Pâ€158: BRAIN NETWORK MODULATION IN ALZHEIMER'S DISEASE AND BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA WITH ELECTRICAL STIMULATION: A PILOT DOUBLEâ€BLIND RANDOMIZED TRIAL. Alzheimer's and Dementia, 2019, 15, P126.	0.8	0
474	IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease. Lancet Neurology, The, 2019, 18, 519-520.	10.2	0
475	Brain imaging working group summaries for the European Joint Programme for Neurodegenerative Disease Research. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 67-68.	2.4	0
476	Amygdalar nuclei and hippocampal subfields on MRI: Testâ€retest reliability of automated segmentation in old and young healthy volunteers. Alzheimer's and Dementia, 2020, 16, e040322.	0.8	0
477	Position Statement on Anti-Dementia Medication for Alzheimer's Disease by Swiss Stakeholders. Clinical and Translational Neuroscience, 2021, 5, 14.	0.9	0
478	Dataâ€driven cutâ€off values for ¹⁸ â€Fâ€AVâ€45 tau PET staging in AD. Alzheimer's and Dementia, 2021, 17, .	0.8	0
479	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. Alzheimer's and Dementia, 2021, 17, .	0.8	0